Endocarditis staphylococcal – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 17 Jun 2026 04:02:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Endocarditis staphylococcal – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Comparing rifampin-free treatment versus rifampin in adults with staphylococcal prosthetic valve endocarditis https://clinicaltrials.eu/trial/comparing-rifampin-free-treatment-versus-rifampin-in-adults-with-staphylococcal-prosthetic-valve-endocarditis/ Wed, 29 Apr 2026 15:06:32 +0000 https://clinicaltrials.eu/trial/comparing-rifampin-free-treatment-versus-rifampin-in-adults-with-staphylococcal-prosthetic-valve-endocarditis/ This study focuses on treating staphylococcal prosthetic valve endocarditis, which is a serious infection of artificial heart valves caused by staphylococcus bacteria. The research compares two different treatment approaches: one using medications without rifampin and another that includes rifampin. The main purpose is to determine if treatment without rifampin works as well as treatment with rifampin in preventing deaths within 6 months of starting therapy.

The study medications include several antibiotics: ceftaroline fosamil, cefazolin, vancomycin, daptomycin, levofloxacin, and cotrimoxazole. Some patients will receive rifampin (either as Rifadine or Rimactan) while others will receive a placebo. The treatment will continue for up to 6 months, with different combinations of these medications given either by mouth or through an intravenous line.

During the study, doctors will monitor patients for signs of infection clearing, complications, and overall health status. They will check if the infection returns, if additional surgery is needed, and track any side effects from the medications. Patients will be followed for up to 12 months to ensure long-term effectiveness of the treatment.

]]>